COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT03041285




Registration number
NCT03041285
Ethics application status
Date submitted
20/01/2017
Date registered
2/02/2017
Date last updated
20/09/2019

Titles & IDs
Public title
Idronoxil Suppository Combine With Radiotherapy for Metastatic Prostate Cancer
Scientific title
Phase I Study of Idronoxil Combined With Radiation Treatment in Men With Metastatic Prostate Cancer
Secondary ID [1] 0 0
NOX66 version 1
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Metastatic Castrate- Resistant Prostate Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Prostate

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - idronoxil (NOX66) suppository
Treatment: Other - Stereotactic Body Radiation Therapy

Experimental: Group 1 NOX66 400mg and SBRT - Group 1 patients will receive 400mg of Idronoxil (NOX66) suppository (1 suppository) daily from Day 0 (1 day before radiotherapy) until 7 days after completion of radiotherapy. Stereotactic Body Radiation Therapy will be given on Days1-5 (5 fractions). Total treatment course is 13-15 days, depends on whether radiotherapy is given on consecutive days or over the weekend.

Experimental: Group 2 NOX66 800mg and SBRT - Group 2 patients will receive 800mg of Idronoxil (NOX66) suppository (2 suppositories) daily from Day 0 (1 day before radiotherapy) until 7 days after completion of radiotherapy. Stereotactic Body Radiation Therapy will be given on Days1-5 (5 fractions). Total treatment course is 13-15 days, depends on whether radiotherapy is given on consecutive days or over the weekend.


Treatment: Drugs: idronoxil (NOX66) suppository
Patients in Group 1 will be given 400mg of Idronoxil suppository (NOX66) (1 suppository) daily from Day 0(1 day before radiotherapy) until 7 days after radiotherapy. Group 2 will be given Idronoxil (NOX66) 800mg (2 suppositories) daily from Day 0 until 7 days after radiotherapy.
All patients will receive one course of Stereotactic Body Radiation Therapy (SBRT), to be delivered in 20 Gray in 5 fractions.
Radiotherapy session will involve irradiation of 1-2 lesions.
.

Treatment: Other: Stereotactic Body Radiation Therapy
All patients (Group 1 and Group 2) will receive one course of Stereotactic Body Radiation Therapy (SBRT), to be delivered in 20 Gray in 5 daily fractions on consecutive days. Radiotherapy session (week 1) will involve irradiation to 1-2 lesions.

Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
safety of Idronoxil dose escalation - Toxicity and relationship with study drug NOX66 will be assessed using Common Terminology Criteria for Adverse Events (CTCAE) V4.3
Timepoint [1] 0 0
From start of NOX66 with stereotactic radiotherapy up to three months post treatment.
Secondary outcome [1] 0 0
evidence of clinical tumour response - PSMA-PET CT will be done before and 3 months after treatment. The change in SUV in PSMA PET will be used to assess tumour metabolic response.
Pre and post treatment tumour size on CT will be measured and RECIST criteria will be used to measure tumour response.
Timepoint [1] 0 0
3 months post treatment

Eligibility
Key inclusion criteria
- Confirmed metastatic prostate cancer that is castrate-resistant.

- 2-3 lesions suitable for radiotherapy.

- ECOG Performance status 0-2.

- Adequate bone marrow, hepatic and renal function

- At least 4 weeks must have elapsed prior to commencement of idronoxil treatment
since prior chemotherapy, investigational drug or biologic therapy
Minimum age
18 Years
Maximum age
No limit
Gender
Males
Can healthy volunteers participate?
No
Key exclusion criteria
- Chemotherapy regimens with delayed toxicity within the last 4 weeks.

- Any situation where the use of suppository therapy is contra-indicated or
impractical(eg. chronic diarrhoea, colostomy, ulcerative colitis).

- No concurrent systemic chemotherapy or biologic therapy is allowed.

- Psychiatric disorder or social or geographic situation that would preclude study
participation.

- Patient unable to provide consent

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Royal North Shore Hospital - St Leonards
Recruitment postcode(s) [1] 0 0
2065 - St Leonards

Funding & Sponsors
Primary sponsor type
Other
Name
Royal North Shore Hospital
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The aim of the study is to determine the toxicity of Idronoxil (NOX66) when used in
combination with palliative radiotherapy for metastatic prostate cancer
Trial website
https://clinicaltrials.gov/show/NCT03041285
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Thomas Eade
Address 0 0
Northern Sydney Local Health District
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT03041285